Key clinical point: Administering tranexamic acid to high-risk patients undergoing joint replacement surgery does not increase the odds of adverse outcomes.
Major finding: After multivariable analysis, high-risk patients who received tranexamic acid had no significant difference in adverse outcome odds, compared with high-risk patients who did not receive tranexamic acid (odd ratio, 1.00; 95% confidence interval, 0.85-1.18).
Study details: A retrospective case-control study of 38,220 patients who underwent primary total knee or total hip arthroplasty between 2011 and 2017.
Disclosures: The study was funded by the Mayo Clinic’s Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery. No conflicts of interest were reported.
Porter SB et al. J Arthroplasty. 2019 Aug 17.